(Q37763127)

22 August 2017

title

Pneumococcal conjugate vaccine: review of cost-effectiveness studies in Australia, North America and Europe (English)

1 reference

cost-effectiveness analysis

22 August 2017

0 references

1 reference

based on heuristic

inferred from title

pneumococcal conjugate vaccine

1 reference

G Thomas Ray

1

1 reference

22 August 2017

publication date

1 August 2008

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

22 August 2017

published in

1 reference

22 August 2017

volume

8

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

373-393

1 reference

Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Cost Effectiveness of Pneumococcal Vaccination for Infants and Children with the Conjugate Vaccine PnC-7 in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Cost-effectiveness of universal pneumococcal vaccination for infants in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Impact of the pneumococcal conjugate vaccine on otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Discounting in economic evaluations: stepping forward towards optimal decision rules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Discounting health effects in pharmacoeconomic evaluations: current controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Theoretical arguments for the discounting of health consequences: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Need for differential discounting of costs and health effects in cost effectiveness analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Cost-utility analysis of the cochlear implant in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Cost-effectiveness of a routine varicella vaccination program for US children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

What is the price of life and why doesn't it increase at the rate of inflation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Information created to evade reality (ICER): things we should not look to for answers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.4.373

21 January 2018

Identifiers

DOI

10.1586/14737167.8.4.373

1 reference

22 August 2017

1 reference